News blog
Synairgen
- BY: Andrew Hore |
- POSTED: 03/10/2010 |
Respiratory drugs developer Synairgen has started a phase II proof-of-concept study for the treatment of exacerbations of asthma and it has taken on Deloitte‘s pharma licensing team to help it sign up a partner for its technology.
The initial focus was on using inhaled interferon beta to treat rhinovirus infections in asthma and chronic obstructive pulmonary disease (COPD) but management sees a greater opportunity in the flu market. Advanced model work for the treatment of flu will start before the end of the year.
Taking on Deloitte will speed up the process of signing up a partner that can finance the trials for Synairgen’s treatments.
Synairgen had £5m in the bank at the end of June following a £2.93m outflow in the previous year.
At 24.75p a share, Synairgen is valued at £14.8m.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|